P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting

Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting

“…There were a total of 15 publications identified, which covered nine unique clinical trials (12 publications) and three real-world studies ( Table 1 ). 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 Within the clinical trials, there was one phase 1/2 study, 20 four phase 2 studies, 17 , 25 , 26 , 28 and four phase 3 studies. 14 , 15 , 16 , 18 , 22 , 24 , 27 The sample size of the trials ranged from 54 patients to 1253 patients.…”

“… 20 Trial (phase 1/2) - NCT01631552 United States Dec. 2013 54 2L: 9%; 3L: 32%; 4L: 28%; >5: 32% 33% 64 6% N/R N/R 17% N/R N/R 17% Sacituzumab govitecan None Moezi et al. 21 Real world (prospective, observational) United States N/R 383 2L and 3L N/R 66 (mean) N/R N/R N/R N/R N/R N/R N/R Nivolumab Chemotherapy Katakami et al. 22 Trial (phase 3) - NCT01454934 Multinational Sept. 2011 540 2L: 3%; 3L: 42%; 4L: 30%; 5L: 18%; 6L+: 8% N/R 62.0/62.0 N/R N/R N/R 15% N/R N/R N/R Eribulin Physician’s choice Disease progression after platinum-based chemotherapy (lines of treatment not reported) Wills et al.…”

“…Among the three real-world studies, one study each was conducted using data from Colombia, 23 Germany, 19 and the United States. 21 The study sample size ranged from 49 patients to 383. Two of the studies evaluated one treatment regimen (docetaxel + ramucirumab and irinotecan + bevacizumab), 19 , 23 and the other study compared nivolumab with chemotherapy.…”

“…Two of the studies evaluated one treatment regimen (docetaxel + ramucirumab and irinotecan + bevacizumab), 19 , 23 and the other study compared nivolumab with chemotherapy. 21 …”

“…Brief descriptions of the trials and a summary of the patients included are reported in Table 1 . 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 The mean or median reported age in all clinical trials was above 60 years of age. Two studies reported the prevalence of brain metastases in patients, which ranged from 6% to 18.8%.…”